Janux Therapeutics, Inc. (NASDAQ:JANX) Insider Andrew Hollman Meyer Sells 50,000 Shares

Janux Therapeutics, Inc. (NASDAQ:JANX) insider Andrew Hollman Meyer sold 50,000 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The stock was sold at an average price of $45.96, for a total transaction of $2,298,000.00. Following the sale, the insider now owns 67,592 shares in the company, valued at approximately $3,106,528.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Janux Therapeutics Stock Down 0.8 %

Shares of JANX stock traded down $0.37 during mid-day trading on Friday, reaching $46.25. The company’s stock had a trading volume of 541,000 shares, compared to its average volume of 721,396. The company’s 50 day simple moving average is $43.92 and its 200-day simple moving average is $44.52. Janux Therapeutics, Inc. has a 12-month low of $5.65 and a 12-month high of $65.60. The firm has a market capitalization of $2.40 billion, a PE ratio of -37.91 and a beta of 3.57.

Janux Therapeutics (NASDAQ:JANX) last issued its earnings results on Wednesday, August 7th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.20. Janux Therapeutics had a negative net margin of 291.17% and a negative return on equity of 8.78%. The business had revenue of $8.90 million for the quarter, compared to the consensus estimate of $0.77 million. The business’s quarterly revenue was up 709.1% on a year-over-year basis. As a group, research analysts anticipate that Janux Therapeutics, Inc. will post -1.18 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $100.00 price target on shares of Janux Therapeutics in a research note on Monday, September 16th. Stifel Nicolaus assumed coverage on shares of Janux Therapeutics in a research note on Friday, September 6th. They set a “buy” rating and a $70.00 price target on the stock. Scotiabank cut their price target on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a research note on Friday, August 9th. Wedbush reaffirmed an “outperform” rating and set a $74.00 price target on shares of Janux Therapeutics in a research note on Thursday, August 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $63.00 price target on shares of Janux Therapeutics in a research note on Monday, August 19th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $66.13.

Institutional Trading of Janux Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Summit Securities Group LLC bought a new stake in shares of Janux Therapeutics in the second quarter worth $29,000. Amalgamated Bank increased its stake in shares of Janux Therapeutics by 61.1% in the second quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after buying an additional 368 shares during the last quarter. Plato Investment Management Ltd bought a new stake in shares of Janux Therapeutics in the second quarter worth $42,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Janux Therapeutics in the second quarter worth $151,000. Finally, AQR Capital Management LLC bought a new stake in shares of Janux Therapeutics in the second quarter worth $215,000. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.